We are live on ! Find out more
SEEL

Seelos Therapeutics, Inc. Common Stock
SEEL

Delisted

SEEL was delisted on the 15th of October, 2024.

Back to rankings

65 hedge funds and large institutions have $21.3M invested in Seelos Therapeutics, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 13 increasing their positions, 18 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

911% more call options, than puts

Call options by funds: $799K | Put options by funds: $79K

16% less funds holding

Funds holding: 77 → 65 (-12)

28% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 18

35% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 26

35% less capital invested

Capital invested by funds: $33M → $21.3M (-$11.7M)

Holders
65
Holders Change
-12
Holders Change %
-15.58%
% of All Funds
1.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
17
Increased
13
Reduced
18
Closed
26
Calls
$799K
Puts
$79K
Net Calls
+$720K
Net Calls Change
+$57K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$930K
2
UIC
Uniplan Investment Counsel
Wisconsin
+$636K
3
OMC
Oasis Management Company
Cayman Islands
+$576K
4
Mirae Asset Global Investments
Mirae Asset Global Investments
South Korea
+$435K
5
Citadel Advisors
Citadel Advisors
Florida
+$425K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$3.06M
2
WP
Woodline Partners
California
-$1.11M
3
State Street
State Street
Massachusetts
-$969K
4
Vanguard Group
Vanguard Group
Pennsylvania
-$492K
5
Northern Trust
Northern Trust
Illinois
-$466K
Name Holding Trade Value Shares
Change 		Change in
Stake
SG
51
StoneX Group
New York
$10.2K +$10.4K +4 New
Victory Capital Management
52
Victory Capital Management
Texas
$10K – – –
ETC
53
Exchange Traded Concepts
Oklahoma
$10K +$7.81K +3 +300%
VFA
54
Valeo Financial Advisors
Indiana
$10K +$10.4K +4 New
FCI
55
Financial Counselors Inc
Kansas
$7K – – –
ACI
56
Alpha Cubed Investments
California
$7K +$7.81K +3 New
TRCT
57
Tower Research Capital (TRC)
New York
$6K -$5.21K -2 -50%
CHA
58
Carmichael Hill & Associates
Maryland
$6K – – –
BNP Paribas Financial Markets
59
BNP Paribas Financial Markets
France
$5.1K – – –
Legal & General Group
60
Legal & General Group
United Kingdom
$5K -$2.6K -1 -33%
IA
61
IFP Advisors
Florida
$5K – – –
NFSG
62
Newbridge Financial Services Group
Florida
$5K – – –
FIA
63
FNY Investment Advisers
New York
$3K – – –
CG
64
Cutler Group
California
$2K – – –
UBS Group
65
UBS Group
Switzerland
$2K – – –
Fidelity Investments
66
Fidelity Investments
Massachusetts
$2K +$2.6K +1 New
Citigroup
67
Citigroup
New York
$1K -$36.5K -14 Closed
New York State Common Retirement Fund
68
New York State Common Retirement Fund
New York
$1K -$18.2K -7 Closed
BC
69
Bartlett & Co
Ohio
$1K – – –
National Bank of Canada
70
National Bank of Canada
Quebec, Canada
$1K – – –
PA
71
Parallel Advisors
California
$1K – – –
SWM
72
Selective Wealth Management
Virginia
$1K +$2.6K +1 New
WIM
73
Westside Investment Management
California
$879 – – –
BCWM
74
Bartlett & Co Wealth Management
Ohio
$680 – – –
ACP
75
Acuta Capital Partners
California
– -$248K -77 Closed
1 2
3
4

SEEL Hedge Fund Activity: Q2 2022 in Review

65 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q2 2022, worth a combined $21.3M — down 35% from $33M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of SEEL and 17 opened new positions — a net loss of 9 holders — while 18 trimmed existing stakes and 13 added.

The largest buyer was Millennium Management, adding an estimated $930K. The largest seller was BlackRock, cutting an estimated $3.06M.

  • 65 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q2 2022, down from 77 in Q1 2022.
  • Funds reported $21.3M of Seelos Therapeutics, Inc. Common Stock stock for Q2 2022, down 35% quarter-over-quarter.
  • 17 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q2 2022 and 26 closed out, a net change of -9 holders.
  • The largest Seelos Therapeutics, Inc. Common Stock buyer in Q2 2022 was Millennium Management, an estimated $930K added.
  • The largest Seelos Therapeutics, Inc. Common Stock seller in Q2 2022 was BlackRock, an estimated $3.06M sold.

Based on aggregated 13F filings for Q2 2022.